EG17339A - 1,4-dihydro-4-oxonaphthyridine derivatives and salts thereof - Google Patents

1,4-dihydro-4-oxonaphthyridine derivatives and salts thereof

Info

Publication number
EG17339A
EG17339A EG261/85A EG26185A EG17339A EG 17339 A EG17339 A EG 17339A EG 261/85 A EG261/85 A EG 261/85A EG 26185 A EG26185 A EG 26185A EG 17339 A EG17339 A EG 17339A
Authority
EG
Egypt
Prior art keywords
dihydro
salts
oxonaphthyridine derivatives
oxonaphthyridine
derivatives
Prior art date
Application number
EG261/85A
Other languages
English (en)
Inventor
Hirokazu Narita
Yoshinori Konishi
Jun Nitta
Hideyoshi Nagaki
Isao Kitayama
Yoriko Kobayashi
Mikako Shinagawa
Yasuo Watanabe
Akira Yotsuji
Shinzaburo Minami
Isamu Saikawa
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13845280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG17339(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of EG17339A publication Critical patent/EG17339A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
EG261/85A 1984-04-26 1985-04-24 1,4-dihydro-4-oxonaphthyridine derivatives and salts thereof EG17339A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59084963A JPS60228479A (ja) 1984-04-26 1984-04-26 １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩

Publications (1)

Publication Number Publication Date
EG17339A true EG17339A (en) 1989-06-30

Family

ID=13845280

Family Applications (1)

Application Number Title Priority Date Filing Date
EG261/85A EG17339A (en) 1984-04-26 1985-04-24 1,4-dihydro-4-oxonaphthyridine derivatives and salts thereof

Country Status (30)

Country Link
JP (1) JPS60228479A (xx)
KR (1) KR870001693B1 (xx)
AR (1) AR241911A1 (xx)
AT (2) AT389698B (xx)
AU (2) AU565087B2 (xx)
BE (1) BE902279A (xx)
CH (1) CH673458A5 (xx)
CS (1) CS250684B2 (xx)
DD (1) DD238795A5 (xx)
DE (2) DE3546658C2 (xx)
DK (1) DK165877C (xx)
EG (1) EG17339A (xx)
ES (2) ES8700256A1 (xx)
FI (1) FI80453C (xx)
FR (2) FR2563521B1 (xx)
GB (2) GB2158825B (xx)
HU (2) HU197571B (xx)
ID (1) ID21142A (xx)
IL (1) IL75021A (xx)
IT (1) IT1209953B (xx)
LU (1) LU85871A1 (xx)
NL (2) NL187314C (xx)
NO (1) NO162238C (xx)
NZ (1) NZ211895A (xx)
PH (3) PH22801A (xx)
PL (1) PL147392B1 (xx)
PT (1) PT80349B (xx)
RO (2) RO91871B (xx)
SE (2) SE463102B (xx)
ZA (1) ZA853102B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6172753A (ja) * 1984-09-18 1986-04-14 Dainippon Pharmaceut Co Ltd ピリジルケトン誘導体
AT392789B (de) * 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
AU576657B2 (en) * 1985-01-23 1988-09-01 Toyama Chemical Co. Ltd. Naphthyridine and pyridine derivatives
DE3525108A1 (de) * 1985-06-07 1986-12-11 Bayer Ag, 5090 Leverkusen Antibakteriell wirksame chinoloncarbonsaeureester
DE3685157D1 (de) * 1985-06-26 1992-06-11 Daiichi Seiyaku Co Pyridoncarbonsaeurederivate.
US4962112A (en) * 1987-08-04 1990-10-09 Abbott Laboratories 7-(2-methyl-4-aminopyrrolidinyl)naphthryidine and quinoline compounds
IE62600B1 (en) * 1987-08-04 1995-02-22 Abbott Lab Naphtyridine antianaerobic compounds
US4859776A (en) * 1988-03-11 1989-08-22 Abbott Laboratories (S)-7-(3-aminopyrrolidin-1-yl)-1-(ortho, para-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid and method for its preparation
JP2844079B2 (ja) * 1988-05-23 1999-01-06 塩野義製薬株式会社 ピリドンカルボン酸系抗菌剤
DE3934082A1 (de) * 1989-10-12 1991-04-18 Bayer Ag Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel
CA2100242A1 (en) * 1991-01-14 1992-07-15 Soon K. Moon Quinolone compounds and processes for preparation thereof
FR2692577B1 (fr) * 1992-05-26 1996-02-02 Bouchara Sa Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant.
KR940014395A (ko) * 1992-12-09 1994-07-18 강박광 신규한 퀴놀론 유도체 및 그의 제조방법
KR0148277B1 (ko) * 1993-01-18 1998-11-02 채영복 신규한 플루오르퀴놀론계 유도체 및 그의 제조방법
AU4272793A (en) * 1993-04-24 1994-11-21 Korea Research Institute Of Chemical Technology Novel quinolone carboxylic acid derivatives and process for preparing the same
KR950018003A (ko) * 1993-12-09 1995-07-22 스미스클라인 비참 피엘씨 신규한 퀴놀론 유도체 및 그의 제조 방법
US5910498A (en) * 1994-10-20 1999-06-08 Wakunaga Seiyaku Kabushiki Kaisha Pyridonecarboxylic acid derivatives or salts thereof and antibacterial agents comprising the same as active ingredient
PT897919E (pt) 1996-04-19 2004-11-30 Wakunaga Pharma Co Ltd Novos derivados do acido piridonacarboxilico ou seus sais e agentes anti-bacterianos contendo-os como ingrediente activo
KR20000052892A (ko) * 1996-10-30 2000-08-25 빌프리더 하이더 나프티리딘 화합물의 제조 방법 및 신규 중간 생성물
DE19713506A1 (de) 1997-04-01 1998-10-08 Bayer Ag Verfahren zur Herstellung von 2,6-Dichlor-5-fluornicotinonitril und die chemische Verbindung 3-Cyano-2-hydroxy-5-fluorpyrid-6-on-mononatriumsalz sowie dessen Tautomere
RU2270695C2 (ru) 1999-03-17 2006-02-27 Дайити Фармасьютикал Ко., Лтд. Фармацевтическая композиция
US6441182B1 (en) 1999-06-10 2002-08-27 Bayer Aktiengesellschaft Method for the production of 2,6-dichloro-5-fluoro-nicotinic acid and coarse and particularly pure 2,6-dichloro-5-fluoro-nicotinic acid
JP3477466B2 (ja) 1999-09-02 2003-12-10 湧永製薬株式会社 キノリンカルボン酸誘導体又はその塩
AU2001286852A1 (en) * 2000-08-29 2002-03-13 Chiron Corporation Quinoline antibacterial compounds and methods of use thereof
KR100981351B1 (ko) * 2003-10-29 2010-09-10 주식회사 엘지생명과학 7-클로로-1-사이클로프로필-6-플루오로-4-옥소-1,4-디하이드로-1,8-나프티리딘-3-카복실산의 제조방법
CN101792443A (zh) * 2010-03-09 2010-08-04 北京欧凯纳斯科技有限公司 氟代喹诺酮衍生物及其制备方法和用途
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN114369092A (zh) * 2021-12-20 2022-04-19 赤峰万泽药业股份有限公司 甲苯磺酸妥舒沙星及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2125310A1 (en) * 1971-05-21 1972-11-30 Sterling Drug Inc , New York, NY (V St A) 1-alkyl-1,4-dihydro-4-oxo-1,8-naphtyridine 3-carboxylic acids antibac
AR223983A1 (es) * 1978-08-25 1981-10-15 Dainippon Pharmaceutical Co Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico
DE3033157A1 (de) * 1980-09-03 1982-04-01 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-naphthyridin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4382937A (en) 1981-02-27 1983-05-10 Dainippon Pharmaceutical Co., Ltd. Naphthyridine derivatives and their use as anti-bacterials
IE55898B1 (en) * 1982-09-09 1991-02-14 Warner Lambert Co Antibacterial agents
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
IL74064A (en) * 1984-01-26 1988-09-30 Abbott Lab 1,7-disubstituted-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives and antibacterial compositions containing them
AU576657B2 (en) * 1985-01-23 1988-09-01 Toyama Chemical Co. Ltd. Naphthyridine and pyridine derivatives
DE3525108A1 (de) * 1985-06-07 1986-12-11 Bayer Ag, 5090 Leverkusen Antibakteriell wirksame chinoloncarbonsaeureester

Also Published As

Publication number Publication date
CH673458A5 (xx) 1990-03-15
FR2614620A1 (fr) 1988-11-04
GB8510297D0 (en) 1985-05-30
NL187314C (nl) 1991-08-16
HUT38634A (en) 1986-06-30
DK165877B (da) 1993-02-01
IL75021A (en) 1994-01-25
HU194226B (en) 1988-01-28
FI80453C (fi) 1990-06-11
RO95509B (ro) 1988-10-01
DD238795A5 (de) 1986-09-03
NO162238C (no) 1989-12-06
DE3514076C2 (xx) 1989-03-30
IT8548002A0 (it) 1985-04-26
ES8700256A1 (es) 1986-09-16
JPS6320828B2 (xx) 1988-04-30
FR2563521B1 (fr) 1989-02-03
SE8804586L (sv) 1988-12-20
ES542584A0 (es) 1986-09-16
SE463102B (sv) 1990-10-08
SE501412C2 (sv) 1995-02-13
PH22801A (en) 1988-12-12
DK185685A (da) 1985-10-27
DK165877C (da) 1993-06-21
ATA267888A (de) 1989-09-15
AU612993B2 (en) 1991-07-25
RO91871B (ro) 1987-07-31
ID21142A (id) 1999-04-29
FI80453B (fi) 1990-02-28
AU8180487A (en) 1988-03-24
AT389698B (de) 1990-01-10
AT390258B (de) 1990-04-10
NL9100648A (nl) 1991-08-01
NO162238B (no) 1989-08-21
GB2158825A (en) 1985-11-20
PT80349B (pt) 1987-09-30
PL253108A1 (en) 1985-12-17
ES8706673A1 (es) 1987-07-01
GB2191776A (en) 1987-12-23
FR2563521A1 (fr) 1985-10-31
PT80349A (en) 1985-05-01
SE8502017D0 (sv) 1985-04-25
DK185685D0 (da) 1985-04-25
DE3514076A1 (de) 1985-10-31
RO91871A (ro) 1987-07-30
IT1209953B (it) 1989-08-30
FR2614620B1 (fr) 1990-03-09
JPS60228479A (ja) 1985-11-13
AR241911A1 (es) 1993-01-29
DE3546658C2 (xx) 1992-04-02
NL8501172A (nl) 1985-11-18
ES551538A0 (es) 1987-07-01
LU85871A1 (en) 1985-12-16
PH25228A (en) 1991-03-27
SE8804586D0 (sv) 1988-12-20
GB2191776B (en) 1990-03-28
NZ211895A (en) 1988-07-28
HU197571B (en) 1989-04-28
PL147392B1 (en) 1989-05-31
BE902279A (fr) 1985-10-25
AU565087B2 (en) 1987-09-03
AU4165085A (en) 1985-10-31
GB8716897D0 (en) 1987-08-26
NO851643L (no) 1985-10-28
KR870001693B1 (ko) 1987-09-24
GB2158825B (en) 1989-01-25
FI851637A0 (fi) 1985-04-25
IL75021A0 (en) 1985-08-30
KR850007596A (ko) 1985-12-07
ZA853102B (en) 1986-12-30
RO95509A (ro) 1988-09-30
ATA122485A (de) 1989-06-15
CS250684B2 (en) 1987-05-14
PH25046A (en) 1991-01-28
FI851637L (fi) 1985-10-27
SE8502017L (sv) 1985-10-27

Similar Documents

Publication Publication Date Title
GB2158825B (en) 1,4-dihydro-4-oxonaphthyridine derivatives and salts thereof
GB2153821B (en) 3-imidazolylmethyl-1,2,3,9-tetrahydro-4h-carbazol-4-one derivatives
ZA856387B (en) Analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives
EP0202580A3 (en) 3,4-dihydrobenzopyran derivatives
ZA869591B (en) Substituted 5,6-dialkoxyquinazoline derivatives
EP0323441A3 (en) 5-fluorouracil derivatives
EP0183975A3 (en) 5,6,7,8-tetrafluoroanthraquinone derivatives
HK185395A (en) 9,11-Epoxy-21-hydroxypregnane derivatives
IL74595A0 (en) 1,2,4-triazacycloalkadiene derivatives
ZA851952B (en) 3-mercapto-1,2,4-triazacycloalkadiene derivatives
PT78568A (en) 4,4'-alkylenedipiperidine derivatives
GB8523735D0 (en) 1,2-benzoxathiine derivatives
GB2093024B (en) 2,4,8-triazaphenalenium salts and their preparation
AU5067985A (en) 1,2,4-thiadiazole derivatives
GB8530178D0 (en) 1,4-dihydropyridine derivatives
PT80882A (en) 4-substituted-1,2,4,6-thiatrizine derivatives
GB8507490D0 (en) Preparing 2 2-bishalomethylpenam derivatives
GB2179350B (en) 7-oxo-4-thia-1-azabicyclo3.2.0hept-2-ene derivatives
GB2154238B (en) 2 imidomethyl-penem derivatives
IE841028L (en) 5,6-dihydropyran-2-one derivatives
IE841962L (en) 1,6 - naphtyridinone derivatives
IE841963L (en) 1,6 - naphthyridinone derivatives
GB8407793D0 (en) 13 14 19 20-retrade-hydro derivatives
GB8407794D0 (en) 13 14 19 19 20 20-hexadehydro derivatives
GB8430451D0 (en) 2 6-dioxopiperidine derivatives